Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y
N Engl J Med. 1985 Dec 26;313(26):1617-20. doi: 10.1056/NEJM198512263132601.
We investigated whether captopril, an angiotensin-converting-enzyme inhibitor, would reduce proteinuria in patients with advanced diabetic nephropathy. Captopril (37.5 mg given in divided doses three times daily) was administered to 10 azotemic diabetics with heavy proteinuria. Urinary protein decreased promptly within two weeks (from 10.6 +/- 2.2 to 6.1 +/- 1.4 g per day [mean +/- S.E.M.]; P less than 0.01). The decrease in proteinuria did not coincide with a fall in systemic blood pressure or in the blood glucose concentration. Serum creatinine and potassium values did not change in any of the patients except one. We suggest that captopril caused a decrease in intrarenal hypertension, which contributed to the reduction of urinary protein excretion. The therapeutic value of this intervention remains to be established.
我们研究了血管紧张素转换酶抑制剂卡托普利是否能降低晚期糖尿病肾病患者的蛋白尿。将卡托普利(每日分三次给药,每次37.5毫克)给予10名患有重度蛋白尿的氮质血症糖尿病患者。两周内尿蛋白迅速下降(从每日10.6±2.2克降至6.1±1.4克[平均值±标准误];P<0.01)。蛋白尿的减少与全身血压或血糖浓度的下降不一致。除一名患者外,其他患者的血清肌酐和钾值均未改变。我们认为卡托普利导致肾内高血压降低,这有助于减少尿蛋白排泄。这种干预措施的治疗价值仍有待确定。